via blogs.forbes.com
What has changed is that it's costing a lot more to get a medicine approved, and all the technical efforts at changing that, from combinatorial chemistry to genomics, haven't really had an impact. Also, new drugs are generating less revenue. And one thing you can't see from the graph is that in recent years, many more products are biotech protein medicines, which are far more expensive.
No comments:
Post a Comment